Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Finished Goods (2016 - 2019)

Aptevo Therapeutics' Finished Goods history spans 5 years, with the latest figure at $3.7 million for Q4 2019.

  • For Q4 2019, Finished Goods rose 446.67% year-over-year to $3.7 million; the TTM value through Dec 2019 reached $3.7 million, up 446.67%, while the annual FY2019 figure was $3.7 million, 446.67% up from the prior year.
  • Finished Goods for Q4 2019 was $3.7 million at Aptevo Therapeutics, up from $1.4 million in the prior quarter.
  • Across five years, Finished Goods topped out at $9.1 million in Q4 2015 and bottomed at $64000.0 in Q2 2018.
  • The 5-year median for Finished Goods is $1.2 million (2017), against an average of $2.8 million.
  • The largest annual shift saw Finished Goods crashed 98.95% in 2018 before it soared 670.31% in 2019.
  • A 5-year view of Finished Goods shows it stood at $9.1 million in 2015, then crashed by 97.83% to $197000.0 in 2016, then skyrocketed by 148.73% to $490000.0 in 2017, then surged by 37.76% to $675000.0 in 2018, then surged by 446.67% to $3.7 million in 2019.
  • Per Business Quant, the three most recent readings for APVO's Finished Goods are $3.7 million (Q4 2019), $1.4 million (Q3 2019), and $493000.0 (Q2 2019).